Journal Watch · The Lancet · 2026
Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea.
At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).<h4>Interpretation</h4>In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.<h4>Funding</h4>Abbott Vascular and Boston Scientific.
TL;DR
At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).<h4>Interpretation</h4>In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.<h4>Funding</h4>Abbott Vascular and Boston Scientific.
Key findings
- The Multicenter FLOW-CMD Registry study is registered with ClinicalTrials.gov (NCT05369182).<h4>Findings</h4>Between April 22, 2022, and Nov 19, 2024, 5764 patients were screened and 1003 patients were enrolled (756 men and 247 women).
- Among these patients, coronary microvascular dysfunction was observed in 123 (21·5%) of 573 patients with obstructive epicardial coronary artery disease and in 40 (9·3%) of 430 patients without obstructive epicardial coronary artery disease.
- At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).<h4>Interpretation</h4>In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.<h4>Funding</h4>Abbott Vascular and Boston Scientific.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Obstructive epicardial coronary artery disease was defined as an intermediate stenosis (40-90% diameter stenosis), with fractional flow reserve of 0·80 or less or severe stenosis (>90% of diameter stenosis) treated with revascularisation without fractional flow reserve measurement. Coronary microvascular dysfunction was identified as coronary flow reserve below 2·0 and index of microcirculatory resistance of ≥25. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.
Full abstract (original)
Background: <h4>Background</h4>Coronary microvascular dysfunction often coexists with epicardial coronary artery disease. Data regarding its prevalence and prognosis in patients undergoing invasive coronary angiography are scarce. This study aimed to evaluate the prevalence and prognosis of coronary microvascular dysfunction in patients undergoing clinically indicated invasive coronary angiography in routine practice.<h4>Methods</h4>In this prospective, multicentre cohort study done in seven tertiary medical hospitals in South Korea, consecutive patients aged 18 years and older who were referred for clinically indicated invasive coronary angiography were systematically screened and evaluated by coronary physiological assessment.
What they did: Obstructive epicardial coronary artery disease was defined as an intermediate stenosis (40-90% diameter stenosis), with fractional flow reserve of 0·80 or less or severe stenosis (>90% of diameter stenosis) treated with revascularisation without fractional flow reserve measurement. Coronary microvascular dysfunction was identified as coronary flow reserve below 2·0 and index of microcirculatory resistance of ≥25. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.
Results & conclusions: The Multicenter FLOW-CMD Registry study is registered with ClinicalTrials.gov (NCT05369182).<h4>Findings</h4>Between April 22, 2022, and Nov 19, 2024, 5764 patients were screened and 1003 patients were enrolled (756 men and 247 women). Among these patients, coronary microvascular dysfunction was observed in 123 (21·5%) of 573 patients with obstructive epicardial coronary artery disease and in 40 (9·3%) of 430 patients without obstructive epicardial coronary artery disease. At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).<h4>Interpretation</h4>In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.<h4>Funding</h4>Abbott Vascular and Boston Scientific.
Abstract © the authors / The Lancet (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/s0140-6736(26)00666-5 · PubMed 42167298.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking The Lancet for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this The Lancet study find?
At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).<h4>Interpretation</h4>In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.<h4>Funding</h4>Abbott Vascular and Boston Scientific.
What type of study is this?
It is a cohort / observational clinical study, published in The Lancet in 2026. Obstructive epicardial coronary artery disease was defined as an intermediate stenosis (40-90% diameter stenosis), with fractional flow reserve of 0·80 or less or severe stenosis (>90% of diameter stenosis) treated with revascularisation without fractional flow reserve measurement.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/s0140-6736(26)00666-5. PubMed ID: 42167298. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/coronary-microvascular-dysfunction-and-cardiovascular-outcomes-multicent-006665/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides